Denny Lanfear, Coherus BioSciences CEO

Co­herus pays out $32M for ex­clu­sive US com­mer­cial­iza­tion rights to Eylea biosim­i­lar

Co­herus Bio­Sciences is adding to its pipeline, this time grab­bing com­mer­cial­iza­tion rights for a biosim­i­lar of one of the largest oph­thal­mol­o­gy drugs on the mar­ket.

The biosim­i­lars play­er said Mon­day that it is in­vest­ing €30 mil­lion ($32 mil­lion) up­front to ac­quire the ex­clu­sive US com­mer­cial­iza­tion rights for FYB203, a biosim­i­lar of Re­gen­eron’s block­buster eye drug Eylea. Co­herus bought the com­mer­cial­iza­tion rights from Klinge Bio­phar­ma, which had in-li­censed the can­di­date from Formy­con, a Ger­man biosim­i­lars de­vel­op­er.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.